Posted by Michael Wonder on 21 Sep 2021
FDA approves Lexette for adolescent plaque psoriasis
21 September 2021 - Mayne Pharma is pleased to announce that the U.S. FDA has approved Lexette (halobetasol propionate) foam, 0.05% for use in adolescents.
Lexette, a super potent topical corticosteroid, is now approved for the treatment of plaque psoriasis in patients aged 12 years and older.
